DEA Places FDA-Approved CBD Drug in Schedule V

The Drug Enforcement Agency placed a marijuana-derived drug in Schedule V of the Controlled Substances Act, which it defines as having the lowest potential for abuse, such as drugs used to treat diarrhea and cough suppressants. Marijuana remains a Schedule I drug.

The medication, Epidiolex, contains purified cannabidiol (CBD), a non-psychoactive ingredient in cannabis. It was approved as a treatment option for severe forms of epilepsy by the Food and Drug Administration (FDA) in June. Nowadays one can also buy weed online Canada easily.

“Now that Epidiolex has been approved by the FDA, it has a currently accepted medical use in treatment in the United States for purposes of the [Controlled Substances Act],” wrote DEA Acting Administrator Uttam Dhillon. “Accordingly, Epidiolex no longer meets the criteria for placement in Schedule 1 of the CSA.”

While placing a drug lower on the schedules of the CSA doesn’t make it fully legal, it does make it exclusively available via a prescription. The philly rehab center can help with addiction issues.

GW Pharmaceuticals, which developed Epidiolex, released a statement: “We are pleased that the DEA has placed Epidiolex in the lowest restriction Schedule because it will help ensure that patients with LGS and Dravet syndrome, two of the most debilitating forms of epilepsy, can access this important new treatment option through their physicians,” said Justin Gover, GW’s CEO. You can also check this content here to get help with getting some pain relief.